Immune Globulin Intravenous (Human)-ifas (Panzyga)
Immune Globulin Intravenous (Human)-ifas is an FDA-licensed reference biologic from Octapharma Pharmazeutika Produktionsges.m.b.H.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2018
Reference approved
Reference product
Panzyga Immune Globulin Intravenous (Human)-ifas
Octapharma Pharmazeutika Produktionsges.m.b.H.
- Approved
- Aug 02, 2018
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for Immune Globulin Intravenous (Human)-ifas, in chronological order.
Reference approval
Approval date of the reference Immune Globulin Intravenous (Human)-ifas product.
7 yr 11 mo ago
Frequently asked questions
Are there biosimilars approved for Immune Globulin Intravenous (Human)-ifas (Panzyga)?
No 351(k) biosimilars or interchangeable biosimilars referencing Immune Globulin Intravenous (Human)-ifas are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.